Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. DBV Technologies S.A. (DBVT) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.DBV Technologies S.A. is one of 999 companies in the Medical group. The Medical group currently sits at #4 within the Zacks Sector Rank. The Zacks Secto ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even ...

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it.Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate revisions, etc. -- ...

Exhibit 99.1 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today reported financial results for the First Quarter of 2025. The quarterly and three months financial statements were approved by the Board of Directors on April 30, 2025. Financial Highlights for the First Quarter Ended March 31, 2025 The Company's interim condensed consolidated financial statements for the three months ended March 31, 2025, are p ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________ FORM 10-Q ____________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to _______________ Commission file number 001-36697 DBV TECHNOLOGIES S.A. (Exact name of registrant a ...

Châtillon, France, April 30, 2025   DBV Technologies Reports First Quarter 2025 Financial Results DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today reported financial results for the First Quarter of 2025. The quarterly and three months financial statements were approved by the Board of Directors on April 30, 2025. Financial Highlights for the First Quarter Ended March 31, 2025 The Company’s interim conden ...

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it.The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock alive.Our " ...

Châtillon, France, April 11, 2025 DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the "Company"), today announced: The audited financial statements for the year ended December 31, 2024 were approved by the Board of Directors on April 11, 2025, and present no chan ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________ FORM 10-K ____________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or □ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to ______________ Commission file number 001-36697 DBV TECHNOLOGIES S.A. (Exact name of registrant as spe ...

Core Viewpoint - DBV Technologies announced a financing of up to $306.9 million (€284.5 million) to support the development and potential commercialization of its Viaskin Peanut patch for treating pediatric peanut allergies, contingent upon FDA approval and successful completion of clinical trials [1][3][4]. Financing Details - The financing includes gross proceeds of $125.5 million (€116.3 million) upon closing and up to $181.4 million (€168.2 million) if all warrants are exercised, with an immediate dilution of 22.4% and a maximal dilution of up to 73.7% for existing shareholders [1][4][7]. - The financing was led by several prominent investors, including MPM BioImpact and Adage Capital Management LP, among others [2]. Development and Regulatory Updates - DBV is advancing the Viaskin peanut patch, having aligned with the FDA on safety exposure data required for a Biologics License Application (BLA) for children aged 4 to 7 years, which accelerates the timeline for submission [3][4]. - The VITESSE Phase 3 study, which is the largest study conducted for peanut allergy in this age range, has enrolled 654 subjects, exceeding the original target of 600, enhancing the study's statistical power to over 90% [3][4]. Use of Proceeds - The proceeds from the financing will be allocated for working capital, continued development of the Viaskin Peanut program, preparation and submission of the BLA, and readiness for a potential U.S. launch [1][5][6]. Financial Position and Future Outlook - The company anticipates that the financing will provide sufficient net working capital to meet obligations over the next 12 months and extend financial visibility into 2028, contingent on the successful commercialization of Viaskin Peanut [11][13]. - Current cash reserves are insufficient to cover operating needs for the next 12 months, highlighting the importance of this financing [8][10]. Shareholder Impact - The financing will significantly alter the shareholding structure, with existing shareholders facing substantial dilution if all warrants are exercised [40][41][43]. - Baker Brothers Investments, a major shareholder, will see its ownership change from 22.82% to 17.14% on a non-diluted basis post-offering, and potentially to 25.15% if all warrants are exercised [32][41][43]. Investor Engagement - DBV Technologies will host an investor conference call to discuss the financing and FDA updates, indicating proactive communication with stakeholders [4][49].